Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy

Documenti analoghi

• Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation
  di: Desaphy, Jean-François, et al.
  Pubblicazione: (2016)
• Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes()
  di: Desaphy, Jean-François, et al.
  Pubblicazione: (2013)
• Long-Term Safety and Usefulness of Mexiletine in a Large Cohort of Patients Affected by Non-dystrophic Myotonias
  di: Modoni, Anna, et al.
  Pubblicazione: (2020)
• In vivo evaluation of antimyotonic efficacy of β-adrenergic drugs in a rat model of myotonia
  di: Desaphy, Jean-François, et al.
  Pubblicazione: (2013)
• Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs
  di: Desaphy, Jean-François, et al.
  Pubblicazione: (2014)